thalidomide has been researched along with Hand Dermatoses in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hand Dermatoses: Skin diseases involving the HANDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The main objectives of this double-blind, placebo-controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate-to-severe palmoplantar psoriasis." | 9.27 | Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. ( Barber, K; Bissonnette, R; Bukhalo, M; Delorme, I; Fowler, JF; Gagné-Henley, A; Gooderham, M; Haydey, R; Jenkin, P; Landells, I; Lynde, CW; Pariser, DM; Poulin, Y; Rosoph, LA, 2018) |
| "We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis." | 9.22 | Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical ( Bissonnette, R; Chen, R; Day, RM; Goncalves, J; Pariser, DM; Sebastian, M; Wasel, NR, 2016) |
| "Following a review of the literature, a panel of dermatologists with expertise in the management of psoriasis considered 5 scenarios in which the evidence supporting the use of apremilast to treat moderate psoriasis is insufficient or controversial." | 9.05 | The Use of Apremilast in Psoriasis: A Delphi Study. ( Ara, M; Belinchón, I; Bustinduy, M; Carrascosa, JM; Herranz, P; Rivera, R, 2020) |
| " This chart review evaluated the use of methotrexate alone and in combination with 7 other systemic therapies in 48 patients with palmoplantar psoriasis." | 5.42 | The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. ( Klufas, DM; Strober, BE; Wald, JM, 2015) |
| "The main objectives of this double-blind, placebo-controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate-to-severe palmoplantar psoriasis." | 5.27 | Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. ( Barber, K; Bissonnette, R; Bukhalo, M; Delorme, I; Fowler, JF; Gagné-Henley, A; Gooderham, M; Haydey, R; Jenkin, P; Landells, I; Lynde, CW; Pariser, DM; Poulin, Y; Rosoph, LA, 2018) |
| "We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis." | 5.22 | Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical ( Bissonnette, R; Chen, R; Day, RM; Goncalves, J; Pariser, DM; Sebastian, M; Wasel, NR, 2016) |
| "Following a review of the literature, a panel of dermatologists with expertise in the management of psoriasis considered 5 scenarios in which the evidence supporting the use of apremilast to treat moderate psoriasis is insufficient or controversial." | 5.05 | The Use of Apremilast in Psoriasis: A Delphi Study. ( Ara, M; Belinchón, I; Bustinduy, M; Carrascosa, JM; Herranz, P; Rivera, R, 2020) |
| " This chart review evaluated the use of methotrexate alone and in combination with 7 other systemic therapies in 48 patients with palmoplantar psoriasis." | 1.42 | The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. ( Klufas, DM; Strober, BE; Wald, JM, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Carrascosa, JM | 1 |
| Belinchón, I | 1 |
| Rivera, R | 1 |
| Ara, M | 1 |
| Bustinduy, M | 1 |
| Herranz, P | 1 |
| Bissonnette, R | 2 |
| Haydey, R | 1 |
| Rosoph, LA | 1 |
| Lynde, CW | 1 |
| Bukhalo, M | 1 |
| Fowler, JF | 1 |
| Delorme, I | 1 |
| Gagné-Henley, A | 1 |
| Gooderham, M | 1 |
| Poulin, Y | 1 |
| Barber, K | 1 |
| Jenkin, P | 1 |
| Landells, I | 1 |
| Pariser, DM | 2 |
| Arora, P | 1 |
| Sardana, K | 1 |
| Gautam, RK | 1 |
| Malhotra, P | 1 |
| Navarro-Triviño, FJ | 1 |
| Cuenca-Barrales, C | 1 |
| Vega-Castillo, JJ | 1 |
| Ruiz-Villaverde, R | 1 |
| Mathieu, S | 1 |
| Soubrier, M | 1 |
| Tournadre, A | 1 |
| Dubost, JJ | 1 |
| Nofal, A | 1 |
| Assaf, M | 1 |
| Elakad, R | 1 |
| Fawzy, M | 1 |
| Nofal, E | 1 |
| Wald, JM | 1 |
| Klufas, DM | 1 |
| Strober, BE | 1 |
| Wasel, NR | 1 |
| Goncalves, J | 1 |
| Day, RM | 1 |
| Chen, R | 1 |
| Sebastian, M | 1 |
| Hoverson, AR | 1 |
| Davis, MD | 1 |
| Weenig, RH | 1 |
| Wolanskyj, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis[NCT03741933] | Phase 4 | 0 participants (Actual) | Interventional | 2019-02-28 | Withdrawn (stopped due to The principal investigator left George Washington University and closed the study at their departure.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Hand Dermatoses
| Article | Year |
|---|---|
The Use of Apremilast in Psoriasis: A Delphi Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Consensus; Delphi Technique; Foot Der | 2020 |
2 trials available for thalidomide and Hand Dermatoses
| Article | Year |
|---|---|
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Topics: Double-Blind Method; Efficiency; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged | 2018 |
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical
Topics: Administration, Oral; Adult; Double-Blind Method; Female; Foot Dermatoses; Hand Dermatoses; Humans; | 2016 |
6 other studies available for thalidomide and Hand Dermatoses
| Article | Year |
|---|---|
Low dose thalidomide monotherapy for the treatment of recalcitrant erosive lichen planus.
Topics: Dose-Response Relationship, Drug; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressiv | 2019 |
Chronic hand eczema and hepatogenic pruritus with good response to apremilast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Eczema; Hand Dermatoses; Humans; Mal | 2019 |
Neutrophilic dermatosis of the dorsal hands during thalidomide treatment.
Topics: Aged; Antineoplastic Agents; Hand Dermatoses; Humans; Male; Multiple Myeloma; Neutrophils; Skin Dise | 2014 |
Neutrophilic dermatosis of the dorsal hands: a localized variant of Sweet's syndrome or a distinct entity?
Topics: Antineoplastic Agents; Hand Dermatoses; Humans; Male; Neutrophils; Skin Diseases, Vesiculobullous; T | 2015 |
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyc | 2015 |
Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide.
Topics: Aged; Diagnosis, Differential; Hand Dermatoses; Humans; Immunologic Factors; Lenalidomide; Male; Pri | 2006 |